Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

On Thursday, Moderna Inc (NASDAQ:MRNA) stock is trading higher after the company reported better-than-expected third-quarter ...

Moderna's study looked at the vaccine in adults aged 50 and older, while Pfizer/BioNTech's trial focused on adults aged 18 to 64. Other rivals, meanwhile, include Sanofi/Novavax, which are ...

President-elect Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to ...

Both the Moderna and Pfizer/BioNTech actions are being heard in a Delaware district court. The lawsuits contribute to an ongoing bun fight between various parties involved in mRNA vaccines ...

dosages of the Pfizer-BioNTech vaccine. Other vaccines (such as Moderna) were excluded from analyses. The final older (12-17 ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.

How are the new vaccines different from last fall’s boosters? The updated mRNA vaccines from Moderna and Pfizer-BioNTech target the KP.2 strain, part of the Omicron lineage that began spreading last ...